Weicheng Lu1, Weifeng Hong2, Haibo Qiu3, Zhongguo Zhou4, Zhonglian He5, Weian Zeng1, Weiqiang Zhong1, Jingdun Xie1. 1. State Key Laboratory of Oncology in Southern China, Department of Anesthesiology, Sun Yat-sen University Cancer Center, Collaborative Innovation for Cancer Medicine, Guangzhou, China. 2. Department of Radiotherapy, Zhongshan Hospital, Fudan University, Shanghai, China. 3. State Key Laboratory of Oncology in Southern China, Department of Gastric Surgery, Sun Yat-sen University Cancer Center, Collaborative Innovation for Cancer Medicine, Guangzhou, China. 4. State Key Laboratory of Oncology in Southern China, Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation for Cancer Medicine, Guangzhou, China. 5. State Key Laboratory of Oncology in Southern China, Information Center, Sun Yat-sen University Cancer Center, Collaborative Innovation for Cancer Medicine, Guangzhou, China.
Abstract
BACKGROUND: Liver cancer is one of the most deadly and prevalent cancers. A routine follow-up plan for liver cancer is crucial but limited. In the present study, we aimed to disclose possible risk factors and critical survival time windows for primary liver cancer. METHODS: We enrolled 692 liver cancer patients from Sun Yat-sen University Cancer Center (SYSUCC). Univariate and multivariate logistic regression analyses of cirrhosis and recurrence were conducted. A meta-analysis was utilized to validate an indication of creatinine (CRE) in recurrence. Conditional survival analysis was performed using the Kaplan-Meier method. The results were further verified by the SYSUCC validation cohort and Surveillance, Epidemiology, and End Results (SEER) validation cohort. RESULTS: Our results indicated that A/G, history of hepatitis, history of alcohol consumption and platelet (PLT) might be potential prognostic factors for cirrhosis in liver cancer patients. CRE was significantly correlated with recurrence due to various therapies, especially after transarterial embolization. Moreover, 1.5 years to 2 years may be a critical time window for deterioration in survival rate based on the conditional survival analysis. CONCLUSION: A/G, history of hepatitis, alcohol consumption and PLT may be potential prognostic factors for cirrhosis in liver cancer patients. More attention should be focused on the renal function when treating the patients due to the significant role of CRE. 1.5 years to 2 years is a critical time window for deterioration in survival rate for liver cancer patients that contributes to determining the optimal follow-up plan in the future.
BACKGROUND: Liver cancer is one of the most deadly and prevalent cancers. A routine follow-up plan for liver cancer is crucial but limited. In the present study, we aimed to disclose possible risk factors and critical survival time windows for primary liver cancer. METHODS: We enrolled 692 liver cancer patients from Sun Yat-sen University Cancer Center (SYSUCC). Univariate and multivariate logistic regression analyses of cirrhosis and recurrence were conducted. A meta-analysis was utilized to validate an indication of creatinine (CRE) in recurrence. Conditional survival analysis was performed using the Kaplan-Meier method. The results were further verified by the SYSUCC validation cohort and Surveillance, Epidemiology, and End Results (SEER) validation cohort. RESULTS: Our results indicated that A/G, history of hepatitis, history of alcohol consumption and platelet (PLT) might be potential prognostic factors for cirrhosis in liver cancer patients. CRE was significantly correlated with recurrence due to various therapies, especially after transarterial embolization. Moreover, 1.5 years to 2 years may be a critical time window for deterioration in survival rate based on the conditional survival analysis. CONCLUSION: A/G, history of hepatitis, alcohol consumption and PLT may be potential prognostic factors for cirrhosis in liver cancer patients. More attention should be focused on the renal function when treating the patients due to the significant role of CRE. 1.5 years to 2 years is a critical time window for deterioration in survival rate for liver cancer patients that contributes to determining the optimal follow-up plan in the future.
Authors: Mihir M Shah; Benjamin I Meyer; Kevin Rhee; Rachel E NeMoyer; Yong Lin; Ching-Wei D Tzeng; Salma K Jabbour; Timothy J Kennedy; John L Nosher; David A Kooby; Shishir K Maithel; Darren R Carpizo Journal: J Surg Oncol Date: 2020-06-10 Impact factor: 3.454
Authors: Gaya Spolverato; Yuhree Kim; Aslam Ejaz; Sorin Alexandrescu; Hugo Marques; Luca Aldrighetti; T Clark Gamblin; Carlo Pulitano; Todd W Bauer; Feng Shen; Charbel Sandroussi; George Poultsides; Shishir K Maithel; Timothy M Pawlik Journal: JAMA Surg Date: 2015-06 Impact factor: 14.766
Authors: Kota Sahara; Katiuscha Merath; Diamantis I Tsilimigras; J Madison Hyer; Alfredo Guglielmi; Luca Aldrighetti; Matthew Weiss; Ryan C Fields; George A Poultsides; Shishir K Maithel; Itaru Endo; Timothy M Pawlik Journal: J Surg Oncol Date: 2019-09-24 Impact factor: 3.454
Authors: Nadia D Ali; Kristen Donohue; Shadi Zandieh; Chunxia Chen; Dirk Moore; Elizabeth Poplin; Mihir M Shah; John Nosher; Bin Gui; Salma K Jabbour; Kristen Spencer; Darren R Carpizo Journal: Am J Clin Oncol Date: 2019-06 Impact factor: 2.339
Authors: Hari Nathan; Mechteld C de Jong; Carlo Pulitano; Dario Ribero; Jennifer Strub; Gilles Mentha; Jean-François Gigot; Richard D Schulick; Michael A Choti; Luca Aldrighetti; Lorenzo Capussotti; Timothy M Pawlik Journal: J Am Coll Surg Date: 2010-05 Impact factor: 6.113
Authors: Alessandro Cucchetti; Matteo Zanello; Matteo Cescon; Giorgio Ercolani; Massimo Del Gaudio; Matteo Ravaioli; Gian Luca Grazi; Antonio D Pinna Journal: Ann Surg Oncol Date: 2010-12-07 Impact factor: 5.344